Northridge, CA and Cambridge, United Kingdom - 6 November 2015 — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced that Chief Executive Officer Adam Kelliher will present and participate in a panel discussion at the Third Annual EU Advanced Therapies Investor Day being held Thursday, November 12, 2015 in London.
The meeting is organized by the Alliance for Regenerative Medicine (ARM), co-hosted by GE Healthcare, Cell Therapy Catapult and BioIndustry Association (BIA). This one-day, invitation-only meeting provides unique insights into the investment opportunities available for advanced therapies treatments and tools.
The event will feature talks from clinical and commercial experts addressing the outlook for advanced therapy technologies, as well as how this field has the potential to impact the standard of care in key therapeutic areas. Attendees will also hear from life science investment experts and sector analysts, in addition to presentations by leading European and international advanced therapies companies, including Avita Medical.
In his presentation, Mr. Kelliher will discuss the Company’s proprietary regenerative skin technology, ReCell®, along with recent business and clinical updates, including the Company’s recent USD$53.9m US Government Contract award, receipt of expanded CE Mark authorization in Europe, and recent publications in peer-reviewed journals demonstrating the effectiveness of ReCell in burn healing and aesthetic outcomes.
Mr. Kelliher will also participate in a panel discussion focused on cell therapy commercialization, to discuss the various product development considerations in bringing regenerative technologies like ReCell® to market.
Following are logistical details of Mr. Kelliher’s presentation during the event:
Event: ARM’s EU Advanced Therapies Investor Day
Date: November 12, 2015
Panel Title: Cell Therapy Commercialization
Panel Time: 9:05 a.m. GMT
Presentation Time: 4:00 p.m. GMT
Location: Royal Institute of British Architectsm, 66 Portland Place, London W1B 1AD
“ARM’s EU Advanced Therapies Investor Day is an optimal opportunity to share the latest updates and developments on ReCell® and our business with a concentrated group of investors,” said Mr. Kelliher. “I am honoured to be speaking in the panel discussion and in the meeting overall and look forward to connecting with fellow members of the regenerative medicine community.”
A live-streamed webcast of all panels and company presentations will be available at http://www.eu.arminvestorday.com/webcast and will be published on the event’s website shortly after the conference.
Attendance at this event is complimentary for credentialed investors and members of the media only. If you are interested in attending, please visit http://eu.arminvestorday.com/attend/ or contact Laura Parsons at email@example.com.
ABOUT RECELL® AND RES™
ReCell® is Avita Medical’s unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient’s skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.
ABOUT AVITA MEDICAL LIMITED
Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita’s patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient’s own skin. The Company’s lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. A pivotal US trial is underway, with patient enrollment completion anticipated by the end of 2015. To learn more, visit www.avitamedical.com.
ABOUT THE ALLIANCE FOR REGENERATIVE MEDICINE
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community Today, ARM has more than 225 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
Issued for and on behalf of Avita Medical by Instinctif Partners.
For more information please contact: firstname.lastname@example.org
Sue CharlesManaging Partner